Patents by Inventor Simon MENDEZ

Simon MENDEZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220196538
    Abstract: A device for medical analyses with cellular impedance signal processing comprises a memory (4) arranged to receive pulse data sets, each pulse data set comprising impedance value data that are associated each time with a time marker, these data together representing a curve of cellular impedance values that are measured as a cell passes through a polarized opening, a computer (6) arranged to process a pulse data set by determining a rotation value indicating whether the cell from which this pulse data set has been taken has undergone a rotation during its passage through the polarized opening, and a classifier (8) arranged to retrieve from the computer (6) a given pulse data set, and to use the resulting rotation value to classify the given pulse data set in a rotation pulse data set group (10) or a rotationless pulse data set group (12).
    Type: Application
    Filed: April 24, 2020
    Publication date: June 23, 2022
    Applicants: HORIBA ABX SAS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S), UNIVERSITE DE MONTPELLIER
    Inventors: Pierre TARACONAT, Damien ISEBE, Simon MENDEZ, Franck NlCOUD
  • Patent number: 10335380
    Abstract: The present findings point to mutant HSCs as the cause of BM neuroglial damage that compromises MSC survival and function, critically contributing to MPN pathogenesis. In this sense, the present invention shows that the niche damage triggered by the mutant HSC is essential for the development of a haematopoietic malignancy previously considered to be caused by the HSC alone. Targeting HSC niche-forming MSCs and their neural regulation paves the way to more efficient therapeutic strategies in MPN. For this purpose, the present invention shows that an efficient therapeutic strategy for the treatment of MPN lies on the administration of neuroprotective compounds, such as 4-methylcatechol, capable of protecting BM sympathetic nerve fibers. Additionally, another efficient therapeutic strategy is shown herein as the administration of selective ?3-adrenergic agonists such as BRL37344 or Mirabegron, since this strategy will compensate for deficient sympathetic stimulation of nestin+ MSCs.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: July 2, 2019
    Assignee: CNIC Fundacion Centro Nacional De Investigaciones Cardiovasculares Carlos III
    Inventors: Simon Mendez Ferrer, Lorena Arranz Salas, Joan Isern Marin
  • Publication number: 20160250163
    Abstract: The present findings point to mutant HSCs as the cause of BM neuroglial damage that compromises MSC survival and function, critically contributing to MPN pathogenesis. In this sense, the present invention shows that the niche damage triggered by the mutant HSC is essential for the development of a haematopoietic malignancy previously considered to be caused by the HSC alone. Targeting HSC niche-forming MSCs and their neural regulation paves the way to more efficient therapeutic strategies in MPN. For this purpose, the present invention shows that an efficient therapeutic strategy for the treatment of MPN lies on the administration of neuroprotective compounds, such as 4-methylcatechol, capable of protecting BM sympathetic nerve fibres. Additionally, another efficient therapeutic strategy is shown herein as the administration of selective ?3-adrenergic agonists such as BRL37344 or Mirabegron, since this strategy will compensate for deficient sympathetic stimulation of nestin+ MSCs.
    Type: Application
    Filed: May 12, 2014
    Publication date: September 1, 2016
    Applicant: CNIC Fundacion Centro Nacional De Investigaciones Cardiovasculares Carlos III
    Inventors: Simon Mendez Ferrer, Lorena Arranz Salas, Joan Isern Marin
  • Publication number: 20130022582
    Abstract: The present invention relates to the use of at least one isolated multipotent stem cell for maintaining haematopoiesis in vitro, in which said multipotent stem cell is preferably a mesenchymal stem cell or, more preferably, said mesenchymal stem cell is a mesenchymal stem cell capable of expressing the nestin protein. The present invention also relates to an isolated cell population of adult nestin-positive mesenchymal cells from a mammal, including humans, to the use thereof for producing a drug for maintaining haematopoiesis in a mammal, for the prevention and/or treatment of at least one disease associated with a malfunction in maintaining haematopoiesis in a mammal, and for maintaining and expanding adult haematopoietic stem cells of said mammal, including a human. Furthermore, the present invention also relates to a method for maintaining haematopoiesis in vitro or to a method for evaluating the haematopoietic capacity of a mammal.
    Type: Application
    Filed: October 22, 2010
    Publication date: January 24, 2013
    Applicants: CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES, SERVICIO ANDALUZ DE SALUD, HOSPITAL CLINIC DE BARCELONA
    Inventors: Simón Méndez Ferrer, Álvaro Urbano Ispizua